Abstract:Prostate cancer (PrCa) is characterized by progression from an androgen-dependent phenotype to one that is inevitably androgen independent (AI) and lethal. Recent evidence strongly suggests that the phosphatidylinositol-3-kinase/Akt (PI3K/Akt) and androgen receptor (AR) signalling pathways provide prostatic epithelium with the necessary signalling events to escape the apoptotic response associated with androgen withdrawal therapy. Silencing of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and glycogen synthase kinase β (GSK3 β ) are frequently associated with advanced PrCa systems and likely serve critical roles in promoting AR and PI3K/Akt gain-of-function. That PTEN negatively regulates AR and is sufficient to promote metastatic PrCa in murine models strongly implies its role as a gatekeeper of progressive PrCa. In human PrCa, PTEN loss is correlated with substantial increases in Akt Ser473 and integrin-linked kinase expression, both of which promote Ser 9 phospho-inhibition of GSK3 β and inactivation of apoptotic factors. Sufficient evidence also suggests that GSK3 β is not only a critical regulator of proproliferative signalling but also a promiscuous one as PI3K/Akt pools of GSK3 β are, at least in part, functionally interchangeable with those of the Wnt/ β -catenin pathway. Thus, GSK3 β may serve not only as a mediator of PI3K/Akt activation but may also regulate the potent transactivation and proproliferative effects that Wnt3a and β -catenin confer upon AR. These data suggest that prostate-specific activation of GSK3 β may serve as a viable pharmacological option. Thus, in this review, we emphasize that temporal changes in GSK3 β and PTEN expression during progression to AI PrCa are important factors when considering the potential for therapies targeting the oncogenic contributions of PI3K/Akt and AR signalling pathways.

Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?

Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer

PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications

The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling

PTEN and GSK3 Β : Key Regulators of Progression to Androgen-Independent Prostate Cancer

Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Targeting PI3K/Akt signaling in prostate cancer therapy

PI3K/AKT signaling pathway and cancer: an updated review

The PTEN–PI3K Axis in Cancer

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

The PTEN–PI3K pathway: of feedbacks and cross-talks

Targeting the PI3K pathway in cancer: are we making headway?

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention

Important Roles of PI3K/AKT Signaling Pathway and Relevant Inhibitors in Prostate Cancer Progression

Targeting PI3K/Akt/mTOR Signaling in Cancer

Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer